E18M Stock Overview
ETF Series Solutions - Loncar China BioPharma ETF is an exchange traded fund launched by ETF Series Solutions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ETF Series Solutions - Loncar China BioPharma ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €12.35 |
| 52 Week High | €20.32 |
| 52 Week Low | €12.35 |
| Beta | 0 |
| 1 Month Change | -16.55% |
| 3 Month Change | -15.81% |
| 1 Year Change | -16.33% |
| 3 Year Change | -50.42% |
| 5 Year Change | n/a |
| Change since IPO | -44.04% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| E18M | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | -16.6% | -1.3% | 1.1% |
| 1Y | -16.3% | 24.5% | 6.5% |
Return vs Industry: E18M underperformed the German Capital Markets industry which returned 9.5% over the past year.
Return vs Market: E18M underperformed the German Market which returned 6.3% over the past year.
Price Volatility
| E18M volatility | |
|---|---|
| E18M Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 4.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E18M has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine E18M's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | n/a | loncarfunds.com/chna |
ETF Series Solutions - Loncar China BioPharma ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC. The fund invests in public equity markets of China.
ETF Series Solutions - Loncar China BioPharma ETF Fundamentals Summary
| E18M fundamental statistics | |
|---|---|
| Market cap | €3.72m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs E18M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E18M income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did E18M perform over the long term?
See historical performance and comparison